Clinical Trial Update: Phase 1/2a Study of ANPD001 in Parkinson Disease [Phase 1]

View source ↗

Summary

Aspen Neuroscience is conducting a Phase 1/2a trial of ANPD001 for Parkinson disease. The study is currently enrolling by invitation and is in Phase 1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ANPD001

Snippet

Sponsor: Aspen Neuroscience | Conditions: Parkinson Disease | Phase 1 | Status: ENROLLING_BY_INVITATION